Anthera Pharmaceuticals, Inc., was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.